



***In vitro* Cytotoxicity and Antiplasmodial Activity of Fractions from *Anthocleista djalonensis* A. Chev. Acetone Root Extract**

Ijeoma Solomon Okoro^{1*}, Terrumun Amom Tor-Anyiin¹,
John Ogbaji Igoli¹, Muluh Emmanuel Khan¹ and Mbeh Ubanga Eteng²

¹Department of Chemistry, Federal University of Agriculture, P.M.B 2373, Makurdi, Benue State, Nigeria.

²Department of Biochemistry, Faculty of Sciences, University of Calabar, P.M.B. 1115, Calabar, Cross River State, Nigeria.

Authors' contributions

This work was carried out in collaboration between all authors. Author ISO designed the study, performed the statistical analysis, wrote the protocol and wrote the first draft of the manuscript. Authors ISO, JOI and MUE managed the analyses of the study. Authors MEK and TATA managed the literature searches. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/IJBCRR/2018/36635

Editor(s):

(1) Dr. Hector M. Mora Montes, Professor, Department of Biology, University of Guanajuato, Mexico.

Reviewers:

(1) Voravuth Somsak, School of Allied Health Sciences, Walailak University, Thailand.

(2) Divya. S. Rajan, Christian College, Chengannur, Kerala University, India.

Complete Peer review History: <http://www.sciencedomain.org/review-history/27398>

Original Research Article

Received 05 August 2017
Accepted 26 October 2017
Published 24 November 2018

ABSTRACT

Aim: Malaria caused by *Plasmodium falciparum* is one of the killer diseases in Africa today and the uncontrollable spread of drug resistance and limited drugs with therapeutic efficacy makes it necessary to discover agents against this deadly parasite. Traditionally *Anthocleista djalonensis* root extract is used in the treatment of Malaria in many parts of Africa and has demonstrated to be a source of antiplasmodial agents. This study aims at identifying possible antiplasmodial agents from chromatographic root fractions of *Anthocleista djalonensis* of the Genatianceae family as well as to evaluate their cytotoxicity against *HeLa* cells.

Place and Duration of Study: The study was undertaken in the Department of Organic Chemistry, Rhodes University, Grahamstown, South Africa. The duration period was between March and July 2016.

*Corresponding author: E-mail: ijeomasolomonokoro@gmail.com;

Methodology: The *Anthocleista djalensis* roots were collected from Arochukwu, Abia State, Nigeria. The acetone extract was obtained from successive maceration of the methanol crude extract with hexane, ethyl acetate and acetone. The concentration (1-1000 µg/mL range) of the chromatographic fractions from acetone root extract of *Anthocleista djalensis* were tested for anti-malarial activity against *Plasmodium falciparum* (*P. falciparum*). Cytotoxicity against HeLa cells was also evaluated using Resazurin based assay.

Results: The Five fractions obtained from the chromatographic fractionation of acetone extract labeled A1, A2, A3, A4, and A5 with percentage yield (13.02, 26.66, 24.70, 0.05 and 26.66% respectively) showed excellent anti-plasmodial activity. The anti-malarial bioassay test showed fractions A1, A2, A3, A4 and A5 with IC₅₀ value of 0.0360 ± 0.0100, 8.1299 ± 2.0358, 46.2482 ± 1.2720, 0.0151 ± 0.0010, and 9.8013 ± 0.8171 µg/mL respectively. CC₅₀ values of 44.2010 ± 8.6790, 50.0000 ± 5.6412, 71.6221 ± 2.9600, 36.7212 ± 5.8900 and 0.5132 ± 3.770 µg mL⁻¹ were recorded for fractions A1, A2, A3, A4 and A5 respectively. Fractions were classified as marginally active (A3) showing SI of 1.540 ± 0.0091, partially active (A2 and A5) with SI 6.150 ± 0.0200 and 4.133 ± 0.015 and as active (A1, A4,) exhibiting SI of 1227.805 ± 8.210 and 2431.867 ± 1.589 respectively. A1 and A4 showed SI > 10 and IC₅₀ < 10 µg/mL. Chloroquine, used as a reference anti-malarial drug, tested in parallel had an IC₅₀ of 0.0125 ± 0.0001 µM and was comparable with A1 and A4.

Conclusion: The chromatographic fractions from acetone root extract of *Anthocleista djalensis* are potential sources for anti-malarial agents of lead compounds for the development of anti-plasmodial drugs.

Keywords: Ant plasmodial activity; cytotoxicity; IC₅₀; fractionation; *Anthocleista djalensis*.

1. INTRODUCTION

Medicinal plants contain chemical substances or constituents that have pharmacological activities [1-7]. These activities include anti-cancer [8,9] anti-tumor [10] anti-oxidant [11] and anti-microbial activities [12,2]. Healing with medicinal plants is as old as mankind itself. The connection between man and his search for drugs in nature dates from the far past. Awareness of medicinal plants usage is a result of the many years of struggles against illnesses by which man learned to pursue drugs in barks, seeds, fruit bodies, and other parts of the plants [13]. Contemporary science has acknowledged their active action, and it has included in modern pharmacotherapy a range of drugs of plant origin, known by ancient civilizations and used throughout the millennia. The knowledge of the development of ideas related to the usage of medicinal plants as well as the evolution of awareness has increased the ability of pharmacists and physicians to respond to the challenges that have emerged with the spreading of professional services in facilitation of man's life [13].

The medicinal plant *Anthocleista djalensis*, A. Chev –Gentianaceae is a large tree which grows up to 20 feet; bole up to 4cm in diameter, stilt-rooted, twig sometimes erect, spines above the leaf axils and with white flowers that are scented [14]. Traditionally, the plant is used to treat

wound, malaria, constipation, dysentery, diarrhea, hepatitis, skin infection, and inflammation [15]. Ethnobotanical investigation showed the use of *Anthocleista djalensis* for the treatment of cancer [16]. Three compounds (monoterpene diol, djalonenol and iridoid glucoside djalonenoside) were isolated from *Anthocleista djalensis* [17]. These compounds when tested in addition with six semisynthetic derivatives for cytotoxicity of constituents, djalonenol and iridoid glucoside demonstrated cytotoxic effect on the brain tumor fibroblasts [18]. The root of *A. djalensis* are used traditionally to treat malaria jaundice, diabetes and abscesses [15] Reports of antibacterial and wound healing activity [19,15], *in vitro* anti-helminthic [20] and anti-malarial activity [21,22] of the plant have been published.

Malaria, the most prevalent and most pernicious parasitic disease of humans, is estimated to kill between one and two million people (mainly children) each year [23]. One of the greatest obstacles to the control of malaria has been the spread of resistance to drugs used on a large scale [24]. Chloroquine, though effective as a blood schizontocidal drug, is ineffective or partially effective in resistant cases [25]. The emergence of strains of *Plasmodium falciparum* resistant to chloroquine and many other drugs in succession have stimulated efforts to identify new anti- malarial agents [25].

Previous pharmacological and bioactivity study of *Anthocleista djalensis* root extracts has necessitated this investigation. In this study, the activity of chromatographic fractions from the acetone root extract against *P. falciparum* was assayed and the cytotoxicity on HeLa cells was also evaluated in order to determine the selectivity of anti-malarial action. *Plasmodium falciparum* responsible for malaria in human was quite suitable for this study.

2. MATERIALS AND METHODS

2.1 Plant Materials

The roots of *Anthocleista djalensis* were obtained from Arochukwu, Abia state, Nigeria. The taxonomic classification of the selected plant was established by Mr Ibe Ndukwe of the Taxonomy Section, Forestry Department, Michael Okpara University of Agriculture Umudike, Abia State, Nigeria. Voucher samples of the plants are deposited in their Herbarium. The roots were dried under shade for three weeks.

2.2 Acetone Extract Preparation

The dried plant samples were pulverized to coarse powder using a laboratory mill (Model 4 Arthur Thomas, USA). The 93 g (AF00) was extracted successively with Hexane (4 x 100 mL), Ethyl acetate (4 x 100 mL), acetone (4 x 100 mL) by maceration. The extracts were concentrated individually with Rota vapor at 35°C to give AF01, AF02, AF03, respectively with AF00 as the crude extract.

2.3 Fractionation of Acetone Extract

Acetone extract being the most active of all the extracts was made candidate for column chromatography (The activity of this extract will be published elsewhere). About 30 g of concentrated acetone extract was fractionated using chromatography column. Packaging was done using an 80 g column of silica gel. Best eluents (hexane, dichloromethane and methanol) were used as mobile phase with a gradient system. Eluates were collected in several bottles of 50 mL, each of which was given a number then analyzed by TLC. The spots separated in TLC were observed with 254 nm UV light. The R_f and eluates which had the same pattern spots appearance on TLC were combined as one fraction then concentrated. Percentages of fractions were calculated using the formula:

$$\% \text{ Fraction} = \frac{\text{Weight of Fraction (g)}}{\text{Weight of plant extract}} \times 100$$

2.4 HeLa Cell Culture and Treatment [26]

Human cervix adenocarcinoma cells (*HeLa*) obtained (from ATCC CCL-2 LGC standard Wesel, Germany) were cultured in a 5%CO₂ incubator at 37°C in DMEM medium supplemented with 10% fetal bovine serum and antibiotics (penicillin/streptomycin/fungizone). The cells were split every 3-5 days (when the cells have reached close to full confluency), and were detached from the culture flask surface using trypsin/EDTA, and the majority aspirated off. Medium was added to the flask and the remainder of the cells, and the flask returned to incubation. The confluency and state of the cells were regularly assessed using an inverted light microscope. Cells were cryo-preserved by detaching the cells from the culture flask in trypsin/EDTA, pelleting the cells, transferring them to cryo-tubes in 10% DMSO in fetal bovine serum, and placing the tubes in a -80 freezer. For the cytotoxicity assay a range of concentrations of extract (1-1000 µg mL⁻¹) was used for 24 h treatment for the determination of 50% cytotoxic concentration (CC₅₀).

2.5 In vitro Cytotoxicity Assay

Cytotoxic activity was determined by resazurin reduction based assay [27]. *HeLa* cells were used for the determination of the CC₅₀ value of the cytotoxicity of chromatographic fractions from *Anthocleista djalensis*. To assess the overt cytotoxicity of the compounds, extracts were incubated at various concentrations in 96-well plates containing *HeLa* (human cervix adenocarcinoma) cells for 24 hours. The numbers of cells surviving on drug exposure were also determined by using the resazurin based reagent and reading resorufin fluorescence in a multiwell plate reader. Reagent was prepared by dissolving high purity resazurin in DPBS (pH 7.4) to 0.15 mg/mL. The resazurin solution was filtered and sterilized through a 0.2 µm filter into a sterile, light protected container. The resazurin solution was stored and protected from light at 4°C for frequent use or at -20°C for long term storage. Cells and test compounds were prepared in opaque-walled 96-well plates containing a final volume of 100 µL/well. An optional set of wells were prepared with medium only for background subtraction and instrument gain adjustment. This was incubated for desired period of exposure. 20 µl resazurin solution was

added to each well. This was incubated for 1 to 4 hours at 37°C. The fluorescence was recorded using a 560 nm excitation / 590 nm emission filter set.

2.6 Plasmodium falciparum Cultivation

Chloroquine sensitive and resistant strains of *P. falciparum* 3D7, respectively, obtained from Rhodes University Grahamstown, South Africa was kept in continuous *in vitro* culture according to the modified candle-jar method of Trager and Jensen [28]. Human red blood cells (blood type A+) in RPMI 1640 medium (Sigma Chemical Co., USA) supplemented with 25 mM HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulphonic acid (Sigma), 0.2 per cent sodium bicarbonate (Sigma), and 15 per cent complement inactivated human AB+ serum were used for parasite culture.

2.7 In vitro Antiplasmodial Assay

Anti-malarial test was carried out using the Immunocapture parasite lactate dehydrogenase (IcpLDH) assay method as described by Makler et al. [29]. Extracts with concentration (0.01-100 µg/mL) were added to parasite cultures in 96-well plates and incubated for 48 h in a 37°C CO₂ incubator. After 48 h the plates were removed from the incubator. Twenty µL of culture was removed from each well and mixed with 125 µL of a mixture of Malstat solution and NBT/PES solution in a fresh 96-well plate. These solutions measure the activity of the parasite lactate dehydrogenase (pLDH) enzyme in the cultures. A purple product was formed when pLDH was present, and this product was quantified in a 96-well plate reader by absorbance at 620 nm (Abs₆₂₀). The Abs₆₂₀ reading in each well is thus an indication of the pLDH activity in that well and also the number of parasites in that well. Each sample was tested in duplicates. For each concentration, % parasite viability – the PLDH activity in treated wells relative to untreated controls was calculated.

2.8 Data Analysis

All experiments were performed in duplicates and presented as the Mean ± SD. Statistical analysis of the data was carried out by one way ANOVA (Graph Pad Prism 5.02 Software). A value of p < 0.05, p < 0.01, p < 0.001 and p < 0.0001 were considered to be significant, very significant and highly significant, respectively. Linear regression analysis was used to calculate CC₅₀

and IC₅₀. The antiplasmodial activities of fractions were expressed by the inhibitory concentrations (IC₅₀) of the drug that induced 50% reduction in parasitaemia compared to the control (100 %) parasitaemia. The activity was analysed according to the classification for antiplasmodial activity by Valdes [30]. Therefore extract exhibiting IC₅₀ *P. falciparum* > 100 µg/mL was considered inactive. Extract showing IC₅₀ *P. falciparum* < 100 µg/mL was classified as follows: - Marginally active at SI < 4, partially active at SI 4-10 and active at SI > 10. Active extract showing IC₅₀ *P. falciparum* < 10 µg/mL was to be selected for further bioassay-guided fractionation. Selectivity index was calculated as the ratio of cytotoxicity of extract on *HeLa* cell line (cytotoxicity) to the IC₅₀ of the extract against *P. falciparum* (antiplasmodial activity) strains.

3. RESULTS AND DISCUSSION

3.1 Fractionation of Acetone Extract

Fractionation of the acetone extract using column chromatography produced five fractions (Table 1). Fraction grouping was based on the TLC analysis using hexane, dichloromethane and methanol as eluents. Based on Table 1, the yield of fractions obtained ranged from 0.05-26.66%. Fraction number A2 and A5 had the highest yield of 26.66% followed by fraction A3, A1 and A4. The smallest yield was fraction A4 (0.05%). From the TLC analysis all fractions had many number of spots and none with a single spot. The fractions were observed to have different colours visually. This may be due to different types of constituents found in each fraction.

3.2 In vitro Assays

Cytotoxicity and anti-malarial activity was determined from CC₅₀ and IC₅₀ value of the fractions. The CC₅₀ and IC₅₀ value is always inversely proportional to the cytotoxicity and anti plasmodial activity respectively. This meant the higher the CC₅₀ and IC₅₀ values, the lower the activities and vice versa. The results showed that there was a positive correlation between the concentrations of fractions with the percentage of *HeLa* cells and *P. falciparum* parasite cell viability (Figs. 6 -11).

3.2.1 In vitro cytotoxicity assay

The test results on *HeLa* cells indicated growth inhibition by the fractions of acetone root extract

Table 1. Yield of fractions of *A. djalensis* acetone root extract

| Fractions | Weight | %Yield | Colour of Fractions | Rf |
|-----------|--------|--------|---------------------|------|
| A1 | 3.90 | 13.02 | White | 0.66 |
| A2 | 8.00 | 26.66 | Light yellow | 0.56 |
| A3 | 7.43 | 24.70 | Yellow | 0.62 |
| A4 | 1.50 | 0.05 | Brown | 0.70 |
| A5 | 8.00 | 26.66 | Dark brown | 0.61 |

Rf= Retardation factor

Table 2. Shows the CC₅₀ and IC₅₀ values of all five chromatographic fractions of *A. djalensis* acetone extract

| Fractions | <i>P. falciparum</i> (IC ₅₀) µg/mL | HeLa cells (CC ₅₀) µg/mL | SI | Classification |
|-----------|---|---|------------------------|-------------------|
| A1 | 0.0360 ± 0.0100 | 44.2010 ± 8.6790 | 1227.8055 ± 8.2100** | Active |
| A2 | 8.1299 ± 2.0358* | 50.0000 ± 5.6412** | 6.1500 ± 0.0200**** | Partially active |
| A3 | 46.2482 ± 1.2720** | 71.6221 ± 2.9600** | 1.5400 ± 0.0091**** | Marginally active |
| A4 | 0.0151 ± 0.001 | 36.7212 ± 5.8900 | 2431.8675 ± 1.5890**** | Active |
| A5 | 9.8013 ± 0.8171** | 40.5132 ± 3.7700* | 4.1330 ± 0.0150 | Partially active |
| CON | 0.0125 ± 0.0001 | 18.6430 ± 1.6969 | 1491.2000 ± 3.009 | Active |

A1-A5 = fractions from acetone root extract of *Anthocleista djalensis*. CON = control, IC₅₀ = The half maximal inhibitory concentration, CC₅₀ = The 50% Cytotoxic concentration, SI = selective index. Results were expressed as mean ± STD. *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001 compared to positive control. Marginally active at SI < 4, partially active at SI 4-10 and active at SI > 10

from *A. djalensis*. All Fractions A1, A2, A3, A4 and A5 had CC₅₀ ≤ 100. The highest cytotoxicity activity was demonstrated by A4 with CC₅₀ value of 36.72 µg/mL followed by A5, A1 and A2 with CC₅₀ value of 40.51 µg/mL, 44.20 µg/mL and 50.00 µg/mL respectively. Fraction A3 showed the lowest cytotoxicity with CC₅₀ value of 71.62 µg/mL (Figs. 1-6).

3.2.2 *In vitro* anti-malarial activity

The test results of *in vitro* anti-malarial activity showed that all fractions of *A. djalensis* acetone extract had the ability to inhibit the growth of *P. falciparum* (Fig 7-11). The IC₅₀ values and selectivity indices (SI = ratio of cytotoxicity to anti-malarial activity) of extracts are shown in Table 2. The IC₅₀ values for fractions A1, A2, A3, A4, and A5 were 0.036 µg/mL, 8.129 µg/mL, 46.248 µg/mL, 0.0151 µg/mL and 9.801 µg/mL respectively. Fractions were classified as marginally active (A3) showing SI of 1.540, partially active (A2 and A5) with SI of 6.150 and 4.133 respectively and as active (A1 and A4) exhibiting SI of 1227.805 and 2431.867 respectively. Furthermore, A1 and A4 showed SI > 10 and IC₅₀ < 10 µg/mL. Chloroquine, used as a reference anti-malarial drug, tested in parallel had an IC₅₀ of 0.0125 µM

and was comparable with A1 and A4 (IC₅₀: 0.0360 µg/mL and 0.0151 µg/mL). This showed A1 and A4 as being very prospective fractions to be developed as anti-malarial agents.

3.3 Discussion

Resistance to anti-malarial drugs has often threatened malaria elimination efforts and historically has led to the short-term resurgence of malaria incidences and deaths [31]. Anti-malarial drug resistance develops when spontaneously occurring parasite mutants with reduced susceptibility are selected, and are then transmitted [32]. Chloroquine resistance is associated with mutations in the polymorphic gene encoding a putative chloroquine transporter and located on chromosome "7" [31]. Chloroquine-resistant *Plasmodium falciparum* malaria is a major health problem. *P. falciparum* infections acquired in most of Africa, and some parts of Asia and South America cannot be treated with chloroquine [33]. Increasing drug resistance in *Plasmodium falciparum* and a resurgence of malaria in tropical areas have effected a change in treatment of malaria [34]. A combination of anti-malarial drugs is responsive to *P. falciparum* with high grade resistance to chloroquine. Artemisinin and its semi-synthetic

derivatives are anti-malarial drugs effective against Chloroquine-resistant *P. falciparum* as single therapeutic agents. However, to minimize the risks of recrudescence and the development of resistance, a combination treatment with a second anti-malarial drug is recommended [35]. Newer drug combination of compounds from biodiversity to combat malarial disease and drug resistant strand are urgently needed. The long-established use of quinine and the more recent introduction of artemisinin and its derivatives as highly effective anti-malarials demonstrates that plant species are an important resource for the

discovery of new anti-malarial agents[36]. *Anthocleista djalensis* of Gentianeaceae family is one plant with diverse medicinal uses. Some activities of the leaf stem [22] and roots [15, 21] parts of the plant against malaria have been reported. The phytochemical screening of the root extract of *Anthocleista djalensis* carried out indicated the presence of saponins, flavonoids, tannins, reducing sugar, steroids, phlobatanins, volatile oils and alkaloids which are active components present in the plant that makes it medicinal [36].




Fig. 1. Cytotoxicity of fraction A1 against *HeLa* cells at different concentration (µg/mL)




Fig. 2. Cytotoxicity of fraction A2 against *HeLa* cells at different concentration (µg/mL)




Fig. 3. Cytotoxicity of fraction A3 against *HeLa* cells at different concentration (µg/mL)




Fig. 4. Cytotoxicity of fraction A4 against *HeLa* cells at different concentration (µg/mL)

In vivo activity of the root extracts and fractions against *P. berghei* may have been reported [21], yet this is the first scientific study of the fractions from the root of *Anthocleista djalensis* on *Plasmodium falciparum* (the parasite responsible for human malaria). In this study we investigated the anti-malarial and cytotoxicity activity of acetone chromatographic fractions of *A. djalensis*. Fractions A2, A3, and A5 with low SI (1.33, 1.68 and 1.30) showed that the anti-malarial activity was dependent on the cytotoxicity and independent on the activity against the parasites. While A1 and A4 with high SI (441.25 and 1560.03) meant that activity

against the parasites was attributed to the parasites themselves and not cytotoxicity. According to Soh [37], high selective index means safer therapy. Hence a cutoff point of 4 certified safe anti-malarial use. Whereas, SI greater than 10 and IC_{50} values below 10 µg/mL should be promising sources of anti-malarial molecules. Activity against *HeLa* cells and *P. falciparum* in a high percentage of tested fractions were observed. Activity was directly proportional to the concentration. Obviously, *in vitro* study presumes a direct action on the parasite [38].




Fig. 5. Cytotoxicity of fraction A5 against *HeLa* cells at different concentration (µg/mL)




Fig. 6. Cytotoxicity of all five fractions against *HeLa* cells at different concentration (µg/mL)

Although, anti-malarial activity has been detected in some parts of *A.djalensis* plants like the stem and leaves [22], this is the first report for the chromatographic fractions of acetone root of *A. djalensis* plant. Phytochemical analysis of these fractions from acetone root extract of *A. djalensis* suggests the presence of triterpenoids, flavonoids and anthraquinones [17] as chemical classes with widely demonstrated effective anti-malarial activity [39]. Flavonoids act by inhibiting the fatty acid biosynthesis (FAS II) of the parasite [40,41] as well as inhibiting the influx of *L*-glutamine and myoinositol into infected erythrocytes [42]. Anti-malarial activity of

anthoquinone could be due to nitric oxide generation from macrophages using polysaccharide. In combination of high concentration of this oxide with sub-optimal doses of chloroquine, the parasitaemia in chloroquine resistant malarial infection was suppressed [43]. While triterpenoids mechanism of action is in the arresting of parasite development, inhibition of the hemozoin polymerization on the parasite [44,45] and the lactase dehydrogenase of the *Plasmodium falciparum* (an essential enzyme used to generate energy within the parasite) [46,47].




Fig. 7. Activity of fraction A1 against *P. falciparum* at different concentration of 0.01,0.1,1,10,100 µg/mL

CQ (0.1 ug/mL) was used as positive control and negative control was treated with tween 20. Results were expressed as mean ± STD. **p<0.01, ***p<0.001 and ****p<0.0001 compared to negative control




Fig. 8. Activity of fraction A2 against *P. falciparum* at different concentration of 0.01,0.1,1,10,100 µg/mL

CQ (0.1ug/mL) was used as positive control and negative control was treated with Tween 20. Results were expressed as mean ± STD. *p<0.05, **p<0.01, ***p<0.001 and ****P<0.0001 compared to negative control




Fig. 9. Activity of fraction A3 against *P. falciparum* at different concentration of 0.01,0.1,1,10,100 µg/mL

CQ (0.1ug/mL) was used as positive control and negative control was treated with tween 20. Results were expressed as mean ± STD. **p<0.05, ****p<0.0001 compared to negative control




Fig. 10. Activity of fraction A4 against *P. falciparum* at different concentration of 0.01,0.1,1,10,100 µg/mL

CQ (0.1ug/mL) was used as positive control and negative control was treated with tween 20. Results were expressed as mean ± STD. ***p < 0.01 and ****p < 0.0001 compared to negative control




Fig. 11. Activity of fraction A5 against *P. falciparum* at different concentration of 0.01,0.1,1,10,100 µg/mL

CQ (0.1 ug/mL) was used as positive control and negative control was treated with tween 20. Results were expressed as mean ± STD. **p < 0.01 and ****p < 0.0001 compared to negative control

The high activity of fraction A1 and A4 is an indication that these fractions are promising sources as anti-malarial agents.

4. CONCLUSION

The chromatographic root fractions of *Anthocleista djalensis* showed potent anti-malarial and cytotoxic activities. The results highlighted the safety in the use of the plant of which can become a source of lead compounds of high therapeutic efficacy for malarial diseases. The remarkable anti malarial activity of *A. djalensis* encourages the investigation of native and naturalized African plants to explore as a potential source of anti malarial drugs.

However, fractions were selected for further purification, isolation and identification of active chemical classes with proved efficacy against *P. falciparum*.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Tyler V. Herb of choice: The therapeutic use of phytomedicinals, Pharmaceutical Products Press: New York, NY. 1994;119.

2. Wink M, Ashour ML, El-Readi MZ. Secondary metabolites from plants inhibiting ABC transporters and reversing resistance of cancer cells and microbes to cytotoxic and antimicrobial agents. *Front. Microbiol.* 2012;3:130. DOI: 10.3389/fmicb.2012.00130
3. Kumar S, Malhotra R, Kumar D. Euphorbia hirta: Its chemistry, traditional and medicinal uses, and pharmacological activities. *Pharmacogn Rev.* 2010;4(7): 58–61. DOI: 10.4103/0973-7847.65327 PMID: PMC3249903
4. Atanasov AG, Waltenberger B, Pferschy-Wenzig E, Linder T, Wawrosch C, Uhrin P, et al. Discovery and resupply of pharmacologically active plant-derived natural products: A review. *Biotechnol Adv.* 2015;33(8):1582–1614. DOI: 10.1016/j.biotechadv.2015.08.001 PMID: PMC4748402;EMSID: EMS65118
5. Thimmappa R, Geisler K, Louveau T, O'Maille P, Osbourn A. Triterpene biosynthesis in plants. *Annu Rev Plant Biol.* 2014;65:225–57. DOI: 10.1146/annurev-arplant-050312-120229 PMID 24498976
6. Augustin JM, Kuzina V, Andersen SB, Bak S. Molecular activities, biosynthesis and evolution of triterpenoid saponins. *Phytochemistry.* 2011;72(6):435–57. PMID 21333312; DOI: 10.1016/j.phytochem.2011.01.015
7. Dhami N. Trends in pharmacognosy: A modern science of natural medicines. *Journal of Herbal Medicine.* 2013;3(4): 123–131. DOI: 10.1016/j.hermed.2013.06.001
8. Greenwell M, Rahman PKSM. Medicinal plants: Their use in anticancer treatment. *Int J Pharm Sci Res.* 2015;6(10):4103–4112. DOI: 10.13040/IJPSR.0975-8232.6(10).4103-12 PMID: PMC4650206; EMSID: EMS65383
9. Mohammad S. Anti-cancer agents from medicinal plants Bangladesh *Journal of Pharmacology.* 2006;1(2).
10. Melo JG, Santos AG, Amorim ELC, Nascimento SC, Albuquerque UP. Medicinal plants used as antitumor agents in Brazil: An Ethnobotanical Approach *Evid Based Complement Alternat Med.* 2011; 2011:1-14. PMID 365359 Available:<http://dx.doi.org/10.1155/2011/365359>
11. Van Wyke BE, Wink C, Wink M. *Phytomedicines, herbal drugs and plant poisons of the World.* Royal Botanic Gardens, Kew, UK; University of Chicago Press, USA. 2015;52-80.
12. Ortega-Ramirez LA, Rodriguez-Garcia I, Leyva JM, Cruz-Valenzuela MR, Silva-Espinoza BA, Gonzalez-Aguilar GA. Potential of medicinal plants as antimicrobial and antioxidant agents in food industry: A hypothesis. *J Food Sci.* 2014;79(2):R129-37. DOI: 10.1111/1750-3841.12341 PMID:24446991
13. Petrovska BB. Historical review of medicinal plants usage. *Pharmacogn Rev.* 2012;6(11):1–5 . DOI: 10.4103/0973-7847.95849 PMID: PMC3358962
14. Jensen SR, Schripsema J. Chemotaxonomy and pharmacology of Gentianaceae. In book: *Gentianaceae - Systematics and Natural History*, Chapter: 6, Publisher: Cambridge Univ. Press. 2002;573-631.
15. Okoli AS, Iroegbu CU. Evaluation of extracts of *Anthocleista djalensis*, *Nauclea latifolia* and *Uvaria afzalii* for activity against bacterial isolates from cases of non-gonococcal urethritis. *Journal of Ethnopharmacology.* 2004;92(1):135-44. DOI: 10.1016/j.jep.2003.12.015
16. Gbadamosi, Idayat Titilayo, Erinoso, Sakiru Morenikeji. A review of twenty ethnobotanicals used in the management of breast cancer in Abeokuta, Ogun State, Nigeria. *African Journal of Pharmacy and Pharmacology.* 2016;10(27):546-564. DOI:10.5897/AJPP2015.4327;<http://www.academicjournals.org/AJPP>
17. Onocha PA, Okorie, DA, Connolly JD, Croft DSJ. Monoterpene diol, iridoid, glucoside and dibenzoaldpha-pyrone from *Anthocleista djalensis*. *Photochemistry.* 1995;40(4):1183-1189.
18. Onocha PA, Okorie DA, Connolly JD, Krebs HC, Meier B, Habermehl GG. Cytotoxic activity of the constituents of *Anthocleista djalensis* and their derivatives. *Nigerian Journal of Natural Products and Medicine.* 2003;7:58-60. Available:<http://dx.doi.org/10.4314/njnpm.v7i1.11710>
19. Chah KF, Eze CA, Emuelosi CE, Esimone CO. Antibacterial and wound healing

- properties of methanolic extracts of some Nigerian Medicinal Plants. J Ethnopharmacol. 2006;104:164–7.
20. Nweze NE, Ngongeh LA. *In vitro* Anthelmintic Activity of *Anthocleista djalensis*. Nig Vet J. 2007;28:9–13.
 21. Akpan EJ, Okokon JE, and Etuk IC. Antiplasmodial and antipyretic studies on root extracts of *Anthocleista djalensis* against *Plasmodium berghei*. Asian Pacific Journal of Tropical Disease; 2012. DOI: 10.1016/S2222-1808(12)60009-7;
 22. Basse AS, Okokon JE, Etim EI, Umoh FU, Basse E. Evaluation of the *in vivo* antimalarial activity of ethanolic leaf and stem bark extracts of *Anthocleista djalensis* Indian J Pharmacol. 2009; 41(6):258–261. DOI: 10.4103/0253-7613.59924 PMID: PMC2846499;
 23. White NJ. Antimalarial drug resistance J Clin Invest. 2004;113(8):1084–1092. DOI: 10.1172/JCI200421682; PMID: PMC385418;
 24. Travassos MA, Miriam K. Laufer. Resistance to antimalarial drugs: Molecular, pharmacological and clinical considerations. Pediatr Res. 2009;65(5 Pt 2):64R–70R. DOI: 10.1203/PDR.0b013e3181a0977e PMID: PMC2837525; NIHMSID; NIHMS108692;
 25. Bickii J, Njifutie N, Foyere JA, Basco LK, Ringwald P. *In vitro* antimalarial activity of limonoids from *Khaya grandifoliola* C.D.C. (Meliaceae). J. Ethnopharmacol. 2000;69: 27-33. Available: [https://doi.org/10.1016/S0378-8741\(99\)00117-8](https://doi.org/10.1016/S0378-8741(99)00117-8)
 26. Paul J. Methods in enzymology. Cell culture. edited by Jakoby WB, Pastan IH, Academic Press, New York, San Francisco and Londo. 1979;LVIII:642. ISBN 0 12 1819582.
 27. Pesch KL, Simmert U. Combined assays for lactose and galactose by enzymatic reactions. Milchw. Forsch. 1929;8:551.
 28. Trager W, Jensen JB. Human parasites in continuous culture. Sciences. 1976;193: 673- 5.
 29. Makler MT, Piper RC, Milhous WK. Lactate dehydrogenase and the diagnosis of malaria. Trends in Parasitology. 1998; 14(9):376–377:1. DOI: [http://dx.doi.org/10.1016/S0169-4758\(98\)01284-8](http://dx.doi.org/10.1016/S0169-4758(98)01284-8)
 30. Valdés AF, Martínez JM, Lizama RS, Gaitén YG, Rodríguez DA, Juan Abreu Payrol JA. *In vitro* antimalarial activity and cytotoxicity of some selected cuban medicinal plants. Rev. Inst. Med. trop. S. Paulo. 2010;52(4). Available: <http://dx.doi.org/10.1590/S0036-46652010000400006>
 31. Petersen I, Eastman R, Michael lanzer. Drug-resistant malaria: Molecular mechanisms and implications for public health. FEBS Letters. 2011;585(11):1551-1562 Available: <https://doi.org/10.1016/j.febslet.2011.04.042>
 32. White N. Antimalarial drug resistance and combination chemotherapy. Philos Trans R Soc Lond B Biol Sci. 1999;354:739-749. PMID:10365399; PMID:PMC1692562; DOI: 10.1098/rstb.1999.0426
 33. White NJ. The treatment of malaria. N Engl J Med. 1996;335(11):800-6. DOI: 10.1056/NEJM199609123351107 PMID:8703186;
 34. WHO. WHO briefing on Malaria Treatment Guidelines and artemisinin monotherapies. Geneva: WHO; 2009. Available: <http://www.who.int/malaria/publications/atoz/meetingbriefing19april.pdf>
 35. Wright CW. Plant derived antimalarial agents: New leads and challenges. Phytochemistry Reviews. 2005;4:55–61Springer 2005. DOI: 10.1007/s11101-005-3261-7
 36. Leke L, Onaji RA, Ahmad G, Uchenna OM. Phytochemical screening and antimicrobial activity studies of the root extract of *Anthocleista djalensis* (Cabbage Tree) International Journal of Chemistry. 2012;4(4). DOI: 10.5539/ijc.v4n4p37
 37. Soh PN, Benoit-Vical F. Are West African plants a source of future antimalarial drugs? J Ethnopharmacol. 2007;114:130-40. Available: <https://doi.org/10.1016/j.jep.2007.08.012>
 38. Benoit-Vical F. Ethnomedicine in malaria treatment. I Drugs. 2005;8:45-52. Krettli AU.
 39. Batista R, Silva AJ, Oliveira AB. Plant-derived antimalarial agents: New leads and efficient. Phytomedicines. Part II. Non-Alkaloidal Natural Products Mol. 2009;14: 3037-3072. DOI: 10.3390/molecules14083037

40. Freundlich JS, Anderson JW, Sarantakis D, Shieh HM, Yu M, Valderramos JC, et al. Synthesis, biological activity, and X-ray crystal structural analysis of diaryl ether inhibitors of malarial enoyl acyl carrier protein reductase: part 1: 4'-substituted triclosan derivatives. *Bioorg Med Chem Lett*. 2005;15:5247-5252.
DOI: 10.1016/j.bmcl.2005.08.044
41. Perozzo R, Kuo M, Sidhu ABS, Valiyaveetil JT, Bittman R, Jacobs WR. Structural elucidation of the specificity of the antibacterial agent triclosan for malarial enoyl acyl carrier protein reductase. *Biol Chem*. 2002;277:13106-13114.
DOI: 10.1074/jbc.M112000200
42. Eford BC. L-Glutamine influx in malaria-infected erythrocytes: A target for antimalarials? *Parasitol Today*. 1986;2:309-312.
DOI: 10.1016/0169-4758(86)90126-2
43. Awasthi A, Kumar A, Upadhyay S-N, Yamada T, Matsunaga Y. Nitric oxide protects against chloroquine resistant *Plasmodium yoelii nigeriensis* parasites in vitro. *Exp. Parasitol*. 2003;105:3-4:184-91.
44. Shuaibu MN, Wuyep PA, Yanagi T, Hirayama K, Tanaka T, et al. The use of microfluorometric method for activity-guided isolation of antiplasmodial compound from plant extracts. *Parasitology Research*. 2008;102:1119-1127.
45. Onyeibor O, Croft SL, Dodson HI, Feiz-Haddad M, Kendrick H, et al. Synthesis of some cryptolepine analogues, assessment of their antimalarial and cytotoxic activities, and consideration of their antimalarial mode of action. *Journal of Medicinal Chemistry*. 2005;48:2701-2709.
46. Kirby GC, Paine A, Warhurst DC, Noamese BK, Phillipson JD. *In vitro* and *in vivo* antimalarial activity of cryptolepine, a plant-derived indoloquinoline. *Phytotherapy Research*. 1994;9:359-363.
47. Royer RE, Deck IM, Campos NM, Hunsaker LA, Vander Jagt DL. Biologically active derivatives of Gossypol: Synthesis and antimalarial activities of peracylatedgossylic nitriles. *Journal of Medicinal Chem*. 1986;29:1799-1801.

© 2018 Okoro et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:

The peer review history for this paper can be accessed here:
<http://www.sciencedomain.org/review-history/27398>